# Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.

> **NCT07039526** · PHASE2 · RECRUITING · sponsor: **John Waters** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Cancer
- Gastrointestinal Cancers
- Gynecologic Cancers

## Interventions

- **DRUG:** CYTALUX™ (pafolacianine) injection preoperatively

## Key facts

- **NCT ID:** NCT07039526
- **Lead sponsor:** John Waters
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07039526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07039526, "Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07039526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*